Full Year Results
2012

AstraZeneca

Cautionary statement regarding forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This presentation contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this presentation and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of patents, marketing exclusivity or trade marks, or the risk of failure to obtain patent protection; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that strategic alliances and acquisitions will be unsuccessful; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of failure to manage a crisis; the risk of delay to new product launches; the difficulties of obtaining and maintaining regulatory approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; the risk of environmental liabilities; the risks associated with conducting business in emerging markets; the risk of reputational damage; the risk of product counterfeiting; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; and the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation. Nothing in this presentation should be construed as a profit forecast.

Full Year Results 2012

Pascal Soriot, Chief Executive Officer

AstraZeneca

Agenda

Pascal Soriot
- Opening remarks
- Commercial performance

Briggs Morrison
- Pipeline review

Simon Lowth
- Financial performance 2012
- 2013 guidance

Pascal Soriot
- Observations from 1st 90 days
- Capital Markets day preview

Overview 2012

Achieved financial target	**Revenue**	$27,973m	-15% (CER)
	Core EPS	$6.41	-9% (CER)
	Reported EPS	$4.99	-29% (CER)
	Dividend	$2.80	
Drove Brand performance	**Achieved $600m in CER revenue growth from:**		
		- Symbicort	*- Onglyza*
		- Faslodex	*- Brilinta/Brilique*
		- Iressa	*- Seroquel XR*
Advanced the Pipeline	**Europe**	*Forxiga*, *Zinforo*, *Caprelsa*	
	US	*FluMist* Quadrivalent	
	Japan	*Symbicort SMART, Symbicort COPD, Nexium + LDA*	
Accelerated Business Development	**Amgen collaboration** (5 clinical projects)		
	Ardea acquisition (Lesinurad in Phase III for gout)		
	Expanded diabetes alliance (Amylin portfolio)		

Regional revenue performance FY 2012

	2012 $m	CER growth	CER $m	
Global Revenue	**27,973**	**-15%**	**(4,966)**	**Astra Tech/Aptium (-1.7 pts)**
US	**10,655**	**-21%**	**(2,771)**	*Seroquel IR* (2,647)
Western Europe	**6,486**	**-19%**	**(1,607)**	*(Seroquel IR, Nexium, Atacand & Merrem* generics)
Established ROW	**5,080**	**-14%**	**(802)**	
Japan	2,904	-5%	(152)	
Canada	1,090	-31%	(497)	*(Crestor)*
Other Established ROW	1,086	-12%	(153)	
Emerging Markets	**5,752**	**+4%**	**214**	
Emerging Europe	1,165	+2%	22	(Turkey: gov't price interventions)
China	1,512	+17%	213	Good growth in Russia
Emerging Asia Pacific	923	-3%	(25)	(India: local supply issues)
Other Emerging ROW	2,152	--	4	(Mexico: generics and difficult market) (Brazil: generics for Crestor/Seroquel IR)

Brand revenue performance FY 2012

	2012 $m	CER growth	CER $m	
Global Revenue	**27,973**	**-15%**	**(4,966)**	
Crestor	6,253	-4%	(246)	Excluding Canada +2%
Symbicort	3,194	+5%	157	
Seroquel XR	1,509	+4%	64	
Faslodex	654	+24%	131	
Iressa	611	+12%	69	
Onglyza	323	+53%	112	
Byetta/Bydureon	111	n/m	111	
Brilinta/Brilique	89	+348%	73	
Nexium	3,944	-10%	(422)	
Seroquel IR	1,294	-70%	(3,026)	
Atacand	1,009	-27%	(394)	
Merrem	*396*	-29%	(167)	

Crestor

2012 Sales: $6,253m -4% CER



US

- FY TRx's -1.4%
- Resilient performance post generic atorvastatin

Crestor US: net dynamic volume trend



Source: IMS NPA Market Dynamics, Data Week ending 01/11/13

1 – Retail dynamic volumes only; does not include mail order or long term care business

Crestor: US TRx trend

Resilient performance post multi-source generic atorvastatin



Q4 12: -6%

Simvastatin label change (2H ’11)

Medicaid volumes (2H ’12)

Crestor

2012 Sales: $6,253m -4% CER



US

- FY TRx's -1.4%
- Resilient performance post generic atorvastatin

RoW

- RoW sales $3,089m -9%
  - Adj for LOE in Canada, FY unchanged
- *Crestor* #1 statin in Japan
- Emerging Markets +4%
  - Adj for LOE Brazil/Mexico, +14%

Crestor: Japan

Increasing share of new patients post generic atorvastatin launch



SOURCE: IMS Health Japan; October 2012

Crestor

2012 Sales: $6,253m -4% CER



US

- FY TRx's -1.4%
- Resilient performance post generic atorvastatin

RoW

- RoW sales $3,089m -9%
  - Adj for LOE in Canada, FY unchanged
- *Crestor* #1 statin in Japan
- Emerging Markets +4%
  - Adj for LOE Brazil/Mexico, +14%

Brilinta

FY 2012 Sales: $89m +348% CER



Now launched in 82 countries

Brilinta: US Launch progress

Steady increase in TRx's



On formulary in more than 60% of Top 400 hospitals

Preferred unrestricted access increased to >50% in Commercial & Medicare Part D managed care plans

Source: IMS Health NPA Weekly

Brilique: Germany

Target hospitals: On protocol in 86%; 39% share of ACS initiations (#1)

OAP Hospital Volume market share
(Daily Dosage)*



OAP Retail Volume market share
(Daily Dosage) *



*market definition: B01C2+Duoplavin+Duocover
Source: IMS DKM national (hospital) and Pharmascope national (retail)

Adjusted to daily dosage:
Brilique: 2 Counting Units (CU) per day
Other OAPs: 1 CU per day

Brilique: France tracking well vs prasugrel launch

Target hospitals: On protocol in 76%; 29% share of ACS initiations (#2)

OAP Hospital Volume market share

Hospital Pharmacy Consumption[1]



Phased on first month of sales :
M0 Efient = Dec 09 ; M0 *Brilique* = June 12

[1] Source: IMS EHPP November 12 (B01C2 OAP market)

OAP Retail Volume market share

sell-out [2]



Phased on first month of sales :
M0 Efient = Jan 10 ; M0 *Brilique* = June 12

[2] Source: IMS December 12 (B01C2 OAP market)

Brilinta

FY 2012 Sales: $89m +348% CER



Now launched in 82 countries

US

- Steady progress in TRx growth
- Preferred, unrestricted access in Commercial and Medicare Part D plans now >50%

RoW

- Continued good performance in Germany
- Good launch uptake in France
- China approval Q4 2012

Onglyza Franchise

FY 2012 Global Alliance Revenue: $323m +53% CER



Source: IMS HEALTH MDART

US

- *Onglyza* franchise TRx volume + 45%
  - DPP4 market growth +22%
- *Onglyza* franchise TRx share 17.8% in December 2012, +1.3 pts
  - *Onglyza* TRx share stable at 11.8%
  - *Kombiglyze XR* share 6.0%

Onglyza: US TRx share increased in growing DPP4 market

Onglyza franchise TRx volume + 45%; TRx share +1.3 pts





Source: IMS Diabetes NPA Monthly Report – Dec

Onglyza Franchise

FY 2012 Global Alliance Revenue: $323m +53% CER



US

- *Onglyza* franchise TRx volume + 45%
  - DPP4 market growth +22%
- *Onglyza* franchise TRx share 17.8% in December 2012, +1.3 pts
  - *Onglyza* TRx share stable at 11.8%
  - *Kombiglyze XR* share 6.0%

RoW

- RoW sales $86m, +56%
- *Kombiglyze XR* launched in Brazil and Mexico
- *Komboglyze* launched in Spain, Germany and France in Q4 2012

Source: IMS HEALTH MDART

Symbicort

2012 Sales: $3,194m +5% CER



US

- US sales reach $1bn milestone for 1st time

Symbicort: US

Steady increase in TRx and New to Combination (NTC) market share



Source for TRx, NRx figures: IMS NPA monthly – December 2012
Source for NTC figures: IMS NPA MD monthly – December 2012

*Average share 2012 compared to average share 2011

Symbicort

2012 Sales: $3,194m +5% CER



US

- US sales reach $1bn milestone for 1st time
- *Symbicort* TRx's +13% vs +1% for fixed combination market
- December 2012 TRx share: 22.3% (+2 pts)
  - New patient share 27.7%

ROW

- FY sales unchanged at $2,191m
- Good market share growth in Japan
  - *Symbicort* SMART and COPD approvals

Nexium

2012 Sales: $3,944m, -10% CER



US

- Steady financial performance in highly generic market
- Volume decline partially offset by higher realised prices due to mix effect

ROW

- FY sales $1,672m, -15%
- LOE in Western Europe
- Strong performance in Japan following lifting of 2-week supply limit within Ryotanki regulations

Nexium Benchmark

Monthly Volume Trend from Launch



Source: IMS B-yen, Nexium; (2012)

Full Year Results
2012

AstraZeneca

Pipeline review 2012

Briggs Morrison, Executive Vice President
Global Medicines Development

AstraZeneca

Driving strategic priorities



Pipeline movement since 2011



R&D pipeline – small and large molecule

Legend

- **Oncology**
- **Respiratory & Inflamm.** (inc. autoimmune.)
- **CVGI**
- **Neuroscience**
- **Infection** (and vaccines)
- **AMGEN/ARDEA**

Phase I

Small	Large
	moxetumomab pasudotox (CD22) haematological malignancies
	MEDI0639 (DLL-4) solid tumours
AZD5363 (AKT) solid tumours	**MEDI3617** (Ang2) solid tumours
AZD2014 (mTOR1&2) solid tumours	**MEDI-565** (CEA BiTE) solid tumours
volitinib (MET) solid tumours	**MEDI6469** (mOx40) solid tumours
AZD1208 (PIM) haematological malignancies	**MEDI4736** (PD-L1) solid tumours
AZD9150 (STAT3) haematological malignancies	**MEDI4212** (IgE) asthma
AZD8330 (MEK) solid tumours	**MEDI7814** (C5/C5a) COPD
AZD8848 (iTLR7) asthma	**MEDI2070** (IL-23) Crohn's
AZD7594 (iSGRM) COPD	**MEDI9929** (TSLP) asthma
AZD1772 (NHE3) end stage renal disease	**MEDI5872** (B7RP1) SLE
AZD1446 (a4b2 NNR) Alzheimer's	**MEDI5117** (IL-6) rheumatoid arthritis
AZD3293 (Beta secretase) Alzheimer's	**MEDI-557** RSV prophylaxis
ATM AVI (BL/BLI) targetted bacterial infection	**MEDI-559** RSV prophylaxis
RDEA3170 (URAT1) gout	**MEDI-550** (PIV) pandemic influenza prophylaxis

LCM/parallel indications in different therapy area to lead *

MEDI-551 (anti-CD19 MAb) multiple sclerosis	

Phase II

Small	Large
selumetinib (MEK) solid tumours	
AZD4547 (FGFR) solid tumours	**MEDI-575** (PDGFrα) NSCLC
olaparib (PARP) gBRCA ovarian cancer	**MEDI-551** (CD19) haematological malignancies
AZD5423 (iSGRM) COPD	**tremelimumab** (CTLA-4) solid tumours
AZD5069 (CXCR2) asthma	**MEDI-573** (IGF) MBC
AZD2115 (MABA) COPD	**benralizumab** (IL-5R) asthma/COPD
AZD3241 (MPO) Parkinson's disease	**mavrilimumab** (GM-CSFR) rheumatoid arthritis
AZD6765 (NMDA) MDD	**MEDI8968** (IL-1R) COPD
AZD3480 (a4b2 NNR) Alzheimer's	**sifalimumab** (IFNa) SLE
AZD5213 (H3R) Alzheimer's	**tralokinumab** (IL-13) asthma/IPF
CXL (BLI /cephalosporin) MRSA	**MEDI-546** (IFNaR) SLE
AZD5847 (Oxazolidine antibacterial inhibitor)TB	**MEDI7183** (α4β7) ulcerative colitis, Crohn's

fostamatinib (SYK) haematological malignancies	**tralokinumab** (IL-13) ulcerative colitis

Phase III – Registration

Small	Large
Caprelsa (VEGFR/EGFR) medullary thyroid cancer	
fostamatinib (SYK) rheumatoid arthritis	
Forxiga (SGLT2) type 2 diabetes	
Brilinta (ADP) arterial thrombosis	
metreleptin (leptin analogue) lipodystrophy	
naloxegol (oral peripherally-acting mu-opioid antagonist) Opioid-induced constipation	
Zinforo (cephalosporin) pneumonia/skin infections	
CAZ AVI (BLI /cephalosporin) serious infections	**FluMist Quadrivalent** Q/LAIV flu vaccine
lesinurad (URAT1) gout	**brodalumab** (IL-17R) psoriasis

11 further LCM opportunities

- **Faslodex** 1st line advanced breast cancer (FALCON)
- **Iressa** treatment beyond progression (IMPRESS)
- **Symbicort** Breath Actuated Inhaler asthma/COPD
- **Brilinta** outcomes study in PAD (EUCLID)
- **Brilinta** outcomes study MI (PEGASUS-TIMI 54)
- **Bydureon** outcomes study (EXSCEL)
- **Bydureon** Dual Chamber Pen
- **Forxiga** high CV risk
- **Forxiga** triple therapy
- **SaxaDapa** diabetes
- **Onglyza** outcomes study (SAVOR-TIMI 53)

* Project count excludes 8 LCM projects under first regulatory review or approved/launched in at least one major market ; excludes Symbicort pMDI LABA postmarketing safety study

Pipeline progress in 2012

Programme	Indication	2012 achievement	Timing
Caprelsa	medullary thyroid cancer	Launch in Europe	H1
Symbicort SMART	asthma	Launch in Japan	
Nexium low dose aspirin	prevention of recurrence of peptic ulcer	Launch in Japan	
Zinforo	skin and soft tissue infections and community acquired pneumonia	Launch in Europe	H2
Symbicort Turbuhaler	chronic obstructive pulmonary disease	Launch in Japan	
Oxis	chronic obstructive pulmonary disease	Launch in Japan	
Forxiga	type 2 diabetes	Launch in Europe	
Komboglyze	type 2 diabetes	Launch in Europe	
FluMist Quadrivalent	flu vaccine	Approval in US	H1
Brilinta	acute coronary syndrome	Approval in China	H2
FluMist Quadrivalent	flu vaccine	Regulatory submission in Europe	
Forxiga/metformin (fixed dose combination)	type 2 diabetes	Regulatory submission in Europe	
Forxiga	type 2 diabetes (add-on to dipeptidyl peptidase-4)	Regulatory submission in Europe	
Forxiga	type 2 diabetes (add-on to insulin)	Regulatory submission in Europe	
Nexium	H. pylori gastritis	Regulatory submission in Japan	
CAZ AVI	serious infections	Phase III start	H1
saxagliptin/dapagliflozin (fixed dose combi.)	type 2 diabetes	Phase III start	
Iressa	treatment beyond progression	Phase III start	
brodalumab	psoriasis	Phase III start	H2
Brilinta	peripheral artery disease	Phase III start	
Nexium	severe reflux oesophagitis	Phase III start (Japan)	
Faslodex	first line metastatic breast cancer	Phase III start	

Late stage – launch products

BRILINTA

Acute coronary syndrome

- Increased investment in PARTHENON programme
- BRILINTA included in 11 sets of global guidelines as part of the standard of care

FORXIGA

Adults with type 2 diabetes

- First in class SGLT2, now launched in UK, Germany and Denmark
- DECLARE cardiovascular outcomes trial will begin to enrol patients in Q2

ONGLYZA

Adults with type 2 diabetes

- SAVOR-TIMI 53 study – 16,500 patients completed in 19 months, two years ahead of schedule
- Complies with new FDA T2DM guidance regarding long-term CV risk

SYMBICORT

Asthma and COPD

- PATHOS real world evidence study compliments strong existing clinical database
- In Japan, SMART launched in June and COPD launched in September

Late stage – phase III

NALOXEGOL	***Opioid induced constipation*** • Top-line results from KODIAC-04 and KODIAC-05, and the KODIAC-07 safety extension trial • On track for regulatory submissions in US, EU, and Canada mid-2013
CAZ AVI	***Serious infections*** • Innovative combination of antibotic ceftazidime and betalactamase inhibitor avibactam • Developed for treatment of hospitalised patients with serious Gram negative bacterial infections
BRODALUMAB	***Psoriasis*** • Phase III initiated in Q3, 2012 • In phase II, high level of response in patients with moderate to severe plaque psoriasis
FOSTAMATINIB	***Rheumatoid arthritis*** • First oral kinase inhibitor with selectivity for spleen tyrosine kinase in development for rheumatoid arthritis • Phase III OSKIRA programme on track to report in Q2, with anticipated filings in the US and EU in Q4
LESINURAD	***Gout*** • Phase III programme started in early 2012, all four studies are actively enrolling • Mechanism of action and tolerability profile could fundamentally change the treatment of gout

What's ahead – potential NME phase III starts 2013-14

2013	2014	
benralizumab – asthma	**AZD6765 –** depression	**ATM AVI –** serious infections
olaparib – solid tumours	**sifalimumab –** systemic lupus erythematosus	**AZD4547 –** solid tumours
moxetumomab pasudotox – hairy cell leukaemia	**mavrilimumab –** rheumatoid arthritis	**AZD1722 –** end stage renal disease
selumetinib – non-small cell lung cancer	**MEDI-551 –** haematological malignancies	**MEDI7183 –** ulcerative colitis
CXL – methicillin-resistant Staphylococcus aureus	**MEDI-575 –** non-small cell lung cancer	**AZD5069 –** asthma
	tralokinumab – asthma	

2013/14 phase III starts for lead indications only

Expected news flow highlights 2013

	Product	Milestone	Timing
NME	fostamatinib – rheumatoid arthritis	Phase III data	H1
	naloxegol – opioid-induced constipation	Phase III data (KODIAC-08)	
	moxetumomab pasudotox – hairy cell leukaemia	Potential phase III start	
	olaparib – solid tumours	Potential phase III start	H2
	CXL – methicillin-resistant Staphylococcus aureus	Potential phase III start	
	benralizumab – asthma	Potential phase III start	
	selumetinib – non-small cell lung cancer	Potential phase III start	
	naloxegol – opioid-induced constipation	Submission for approval in USA & Europe	
	fostamatinib – rheumatoid arthritis	Submission for approval in USA & Europe	
Other	Forxiga – type 2 diabetes (triple therapy)	Submission for approval in Europe	H1
	Brilinta – acute coronary syndrome	Submission for approval in Japan	
	Forxiga – type 2 diabetes	Submission for approval in Japan & China	
	Zoladex – three month depot (breast cancer)	Submission for approval in Japan	
	Onglyza SAVOR-TIMI53 – outcomes study	Study results	H2
	brodalumab – psoriatic arthritis	Potential phase III start	
	Forxiga – type 2 diabetes	Resubmission for approval in USA	
	Onglyza SAVOR-TIMI53 – outcomes study	Submission for approval in USA &Europe	
	Bydureon Dual Chamber Pen – type 2 diabetes	Submission for approval in USA	
	FluMist Quadrivalent – flu vaccine	Launch in US	
	Casodex oral dispersible tablet	Launch in Japan	

Driving strategic priorities



Full Year Results
2012

AstraZeneca

Full Year Results 2012

Simon Lowth, Chief Financial Officer

AstraZeneca

Headline results FY 2012

	2012 $m	2011 $m	Actual growth	CER growth
Revenue	**27,973**	**33,591**	**-17%**	**-15%**
Core Operating Profit	**10,430**	**13,167**	**-21%**	**-18%**
Core EPS	**$6.41**	**$7.28**	**-12%**	**-9%**
Restructuring	($0.94)	($0.63)		
MedImmune/Merck amortisation	($0.40)	($0.32)		
Intangible impairments	-	($0.01)		
Legal provisions & other	($0.08)	$1.01*		
Reported EPS	**$4.99**	**$7.33**	**-32%**	**-29%**

* Includes $1.08 gain from sale of Astra Tech

Headline results Q4 2012

	2012 $m	2011 $m	Actual growth	CER growth
Revenue	**7,282**	**8,656**	**-16%**	**-15%**
Core Operating Profit	**2,532**	**2,990**	**-15%**	**-13%**
Core EPS	**$1.56**	**$1.61**	**-3%**	**+1%**
Restructuring	($0.23)	($0.36)		
MedImmune/Merck amortisation	($0.11)	($0.08)		
Intangible impairments	-	-		
Legal provisions & other	-	($0.01)		
Reported EPS	**$1.22**	**$1.16**	**+5%**	**+10%**

Core margin: FY 2012

	$m	CER growth	% sales	Delta vs PY CER
Revenue	**27,973**	**-15%**		
Core Gross Margin	22,716	-16%	81.2	-90bps
Distribution	(320)	-5%	1.2	-20bps
Core SG&A	(8,541)	-12%	30.5	-90bps
Core Other Income	1,027	+24%	3.7	+110bps
Core Pre-R&D Profit	**14,882**	**-16%**	**53.2**	**-90bps**
Core R&D	(4,452)	-11%	15.9	-70bps
Core Operating Profit	**10,430**	**-18%**	**37.3**	**-160bps**

Restructuring Programme: Phase 3 2012-2014

	Headcount Impact 2012-2014	Programme Cost 2012-2014 $m	Progress to date	
			Costs $m	Headcount
Global Supply Chain	**1,350**	**(500)**	**(136)**	**~750**
SG&A	**3,750**	**(800)**	**(631)**	**~3,250**
R&D	**2,200**	**(800)**	**(791)**	**~2,260**
Total	**~ 7,300**	**(2,100)†**	**(1,558)***	**~ 6,300**

Estimated annual benefits: $1,600m by end 2014
of which ~$350m has been realised by end 2012

* An additional $261m was charged during Q4 2011
† Of which $1.7bn are cash costs

Net headcount developments: 2006-2012



Headcount Dec 31st 2006 (66,800) Headcount Dec 31st 2012 (51,700)

† Includes the acquisition of MedImmune

Cash generation: FY 2012

	2012 $m	2011 $m
Opening net funds	**2,849**	**3,653**
EBITDA	10,666	15,345
Movement in working capital	(706)	(897)
Tax & interest paid	(2,588)	(4,547)
Other non-cash movements	(424)	(597)
Profit on disposal of Astra Tech	-	(1,483)
Net cash from operating activities	**6,948**	**7,821**

Cash application: FY 2012

	2012 $m
Opening net funds	**2,849**
Net cash from operating activities	6,948
Purchased Amylin intangible assets	(3,360)
Other net capex	(1,060)
Dividends/Net share buy-back	(5,871)
Acquisitions	(1,187)
Other movements	312
Closing net funds	**(1,369)**
Gross debt	(10,310)
Cash/Cash equivalents, STIs & Net Derivative Financial Instruments	8,941

Cash distributions

Dividend	• FY 2012 dividend $2.80 per share • Progressive dividend policy confirmed (maintain or grow) • Basis for dividend cover revised to 2x Core earnings (new definition) • Cover likely to vary from the 2x cover target
Share repurchases	• FY 2012: Net $2.2bn prior to suspension • FY 2013: No repurchases planned

Core financials: FY 2012

	Previous definition		*New definition*	
	$m	**% sales**	**$m**	**% sales**
Revenue	**27,973**		**27,973**	
Core Gross Margin	22,716	81.2	23,041	82.4
Distribution	(320)	1.2	(320)	1.2
Core SG&A	(8,541)	30.5	(8,389)	30.0
Core Other Income	1,027	3.7	1,068	3.8
Core Pre-R&D Profit	**14,882**	**53.2**	**15,400**	**55.0**
Core R&D	(4,452)	15.9	(4,241)	15.1
Core Operating Profit	**10,430**	**37.3**	**11,159**	**39.9**
Core EPS	$6.41		$6.87	

Guidance for 2013 (new Core basis)

Revenue (CER)	Mid to High-single digit decline
Core Operating Costs (CER) (R&D + SG&A)	Hold to a slight increase vs 2012
Core Other Income	< $600 million
Reported tax rate	Around 23 percent
Core EPS (CER) *(new definition)*	Decline significantly > revenue decline

Full Year Results
2012

AstraZeneca

Full Year Results 2012

Pascal Soriot, Chief Executive Officer

AstraZeneca

Unique combination of capabilities



R&D pipeline – small and large molecule

Legend

- **Oncology**
- **Respiratory & Inflamm.** (inc. autoimmune.)
- **CVGI**
- **Neuroscience**
- **Infection** (and vaccines)
- **AMGEN/ARDEA**

Phase I

Small	Large
	moxetumomab pasudotox (CD22) haematological malignancies
	MEDI0639 (DLL-4) solid tumours
AZD5363 (AKT) solid tumours	**MEDI3617** (Ang2) solid tumours
AZD2014 (mTOR1&2) solid tumours	**MEDI-565** (CEA BiTE) solid tumours
volitinib (MET) solid tumours	**MEDI6469** (mOx40) solid tumours
AZD1208 (PIM) haematological malignancies	**MEDI4736** (PD-L1) solid tumours
AZD9150 (STAT3) haematological malignancies	**MEDI4212** (IgE) asthma
AZD8330 (MEK) solid tumours	**MEDI7814** (C5/C5a) COPD
AZD8848 (iTLR7) asthma	**MEDI2070** (IL-23) Crohn's
AZD7594 (iSGRM) COPD	**MEDI9929** (TSLP) asthma
AZD1772 (NHE3) end stage renal disease	**MEDI5872** (B7RP1) SLE
AZD1446 (a4b2 NNR) Alzheimer's	**MEDI5117** (IL-6) rheumatoid arthritis
AZD3293 (Beta secretase) Alzheimer's	**MEDI-557** RSV prophylaxis
ATM AVI (BL/BLI) targetted bacterial infection	**MEDI-559** RSV prophylaxis
RDEA3170 (URAT1) gout	**MEDI-550** (PIV) pandemic influenza prophylaxis

LCM/parallel indications in different therapy area to lead *

MEDI-551 (anti-CD19 MAb) multiple sclerosis	

Phase II

Small	Large
selumetinib (MEK) solid tumours	
AZD4547 (FGFR) solid tumours	**MEDI-575** (PDGFrα) NSCLC
olaparib (PARP) gBRCA ovarian cancer	**MEDI-551** (CD19) haematological malignancies
AZD5423 (iSGRM) COPD	**tremelimumab** (CTLA-4) solid tumours
AZD5069 (CXCR2) asthma	**MEDI-573** (IGF) MBC
AZD2115 (MABA) COPD	**benralizumab** (IL-5R) asthma/COPD
AZD3241 (MPO) Parkinson's disease	**mavrilimumab** (GM-CSFR) rheumatoid arthritis
AZD6765 (NMDA) MDD	**MEDI8968** (IL-1R) COPD
AZD3480 (a4b2 NNR) Alzheimer's	**sifalimumab** (IFNa) SLE
AZD5213 (H3R) Alzheimer's	**tralokinumab** (IL-13) asthma/IPF
CXL (BLI /cephalosporin) MRSA	**MEDI-546** (IFNaR) SLE
AZD5847 (Oxazolidine antibacterial inhibitor)TB	**MEDI7183** (α4β7) ulcerative colitis, Crohn's

fostamatinib (SYK) haematological malignancies	**tralokinumab** (IL-13) ulcerative colitis

Phase III – Registration

Small	Large
Caprelsa (VEGFR/EGFR) medullary thyroid cancer	
fostamatinib (SYK) rheumatoid arthritis	
Forxiga (SGLT2) type 2 diabetes	
Brilinta (ADP) arterial thrombosis	
metreleptin (leptin analogue) lipodystrophy	
naloxegol (oral peripherally-acting mu-opioid antagonist) Opioid-induced constipation	
Zinforo (cephalosporin) pneumonia/skin infections	
CAZ AVI (BLI /cephalosporin) serious infections	**FluMist Quadrivalent** Q/LAIV flu vaccine
lesinurad (URAT1) gout	**brodalumab** (IL-17R) psoriasis

11 further LCM opportunities

- **Faslodex** 1st line advanced breast cancer (FALCON)
- **Iressa** treatment beyond progression (IMPRESS)
- **Symbicort** Breath Actuated Inhaler asthma/COPD
- **Brilinta** outcomes study in PAD (EUCLID)
- **Brilinta** outcomes study MI (PEGASUS-TIMI 54)
- **Bydureon** outcomes study (EXSCEL)
- **Bydureon** Dual Chamber Pen
- **Forxiga** high CV risk
- **Forxiga** triple therapy
- **SaxaDapa** diabetes
- **Onglyza** outcomes study (SAVOR-TIMI 53)

* Project count excludes 8 LCM projects under first regulatory review or approved/launched in at least one major market ; excludes Symbicort pMDI LABA postmarketing safety study

Today: 5 key growth platforms

1. *Brilinta*

2. Diabetes

3. Emerging Markets

4. Respiratory



5. Japan

Full Year Results
2012

AstraZeneca